Editorial commentary: Cardiac amyloidosis —Reversing the mindset and the cardiomyopathy
Cardiac amyloidosis has an unfortunate historical reputation as an uncommon disease with a poor prognosis and no treatment options. Anecdotally, this has led to an under-diagnosis and under-referral of patients. Recently, interest from the heart failure and cardiac imaging communities has led to an increase in recognition through multimodality imaging, while pharmaceutical companies have several novel treatment options in clinical trials for both light chain (AL) and transthyretin (ATTR) amyloidosis.
Source: Trends in Cardiovascular Medicine - Category: Cardiology Authors: Brett W. Sperry Source Type: research
More News: Amyloidosis | Cardiology | Cardiomyopathy | Cardiovascular | Clinical Trials | Heart | Heart Failure | History of Medicine